{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:29Z","timestamp":1793908649700,"version":"4.8.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021546","name":"Suez University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021546","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Metabolic (dysfunction) associated fatty liver disease (MAFLD) is a growing global concern. This study assessed the frequency of hepatic steatosis and MAFLD, alongside their associated risk factors, among medical students at Suez University, Egypt. A cross-sectional study was conducted from November 2022 to April 2023 among 84 medical students aged\u2009\u2265\u200918\u00a0years. Data on anthropometric parameters, body composition, and lifestyle were collected through self-administered questionnaires, InBody analysis, and FibroScan. MAFLD diagnosis required steatosis (\u2265\u2009238\u00a0dB\/m) with obesity, metabolic dysfunction, or both. Statistical analyses included chi-square tests, ANOVA, and logistic regression. Hepatic steatosis was present in 25% of participants, while MAFLD frequency was 13.1%. Participants with MAFLD exhibited higher body weight (82.34\u2009\u00b1\u200910.78\u00a0kg vs. 65.84\u2009\u00b1\u200910.61\u00a0kg, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), BMI (29.05\u2009\u00b1\u20093.66 vs. 22.90\u2009\u00b1\u20093.23\u00a0kg\/m<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), waist circumference (88.73\u2009\u00b1\u20098.73\u00a0cm vs. 78.10\u2009\u00b1\u20097.96\u00a0cm, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), BMR (1566.09\u2009\u00b1\u200927.37 vs. 1429.86\u2009\u00b1\u200993.44\u00a0kcal\/day, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and fat mass (32.74\u2009\u00b1\u20097.25% vs. 23.91\u2009\u00b1\u20098.60%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Binary regression analysis revealed increased body weight, BMI, waist circumference, and BMR as significant risk factors for MAFLD. An elevated fat mass percentage with a reduced muscle mass percentage highlighted the sarcopenic obesity role in MAFLD progression. Extreme weight reduction can exacerbate hepatic fat accumulation. Poor sleep quality, a sedentary lifestyle, and an unhealthy diet are also significant predictors. The widespread frequency of steatosis and MAFLD highlights the pressing need to tackle this silent epidemic among young Egyptian adults.<\/jats:p>","DOI":"10.1038\/s41598-025-95753-w","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:12:07Z","timestamp":1744985527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Frequency and risk factors of metabolic associated fatty liver disease among medical students in Egypt"],"prefix":"10.1038","volume":"15","author":[{"given":"Mohamed M.","family":"Elhoseeny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Rageh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar M.","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-0035","authenticated-orcid":false,"given":"Amira A. A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"1","key":"95753_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73(1), 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"issue":"6","key":"95753_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6), 1966\u20131986 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"95753_CR3","first-page":"9","volume":"13","author":"P Paschos","year":"2009","unstructured":"Paschos, P. & Paletas, K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia 13(1), 9 (2009).","journal-title":"Hippokratia"},{"issue":"19","key":"95753_CR4","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.3390\/jcm12196216","volume":"12","author":"W Eskridge","year":"2023","unstructured":"Eskridge, W. et al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective. J. Clin. Med. 12(19), 6216 (2023).","journal-title":"J. Clin. Med."},{"issue":"70","key":"95753_CR5","first-page":"277","volume":"1","author":"B Canbakan","year":"2007","unstructured":"Canbakan, B. et al. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastro-Enterol. Belgica. 1(70), 277\u2013284 (2007).","journal-title":"Acta Gastro-Enterol. Belgica."},{"key":"95753_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00247-014-3024-y","volume":"44","author":"J Deng","year":"2014","unstructured":"Deng, J. et al. Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. Pediatr. Radiol. 44, 1379\u20131387 (2014).","journal-title":"Pediatr. Radiol."},{"issue":"7","key":"95753_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher, G., Tilg, H. & Byrne, C. D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol. Hepatol. 6(7), 578\u2013588 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"95753_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73\u201384 (2016).","journal-title":"Hepatology"},{"issue":"12","key":"95753_CR9","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le, M. H. et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20(12), 2809\u20132817 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"95753_CR10","doi-asserted-by":"publisher","first-page":"102973","DOI":"10.1016\/j.dsx.2024.102973","volume":"18","author":"Y He","year":"2024","unstructured":"He, Y. et al. Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study. Diabetes Metab. Syndr. 18(3), 102973 (2024).","journal-title":"Diabetes Metab. Syndr."},{"issue":"1","key":"95753_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/sjg.sjg_357_21","volume":"28","author":"Y Fouad","year":"2022","unstructured":"Fouad, Y. et al. The Egyptian clinical practice guidelines for the diagnosis and management of metabolic-associated fatty liver disease. Saudi J. Gastroenterol. 28(1), 3\u201320 (2022).","journal-title":"Saudi J. Gastroenterol."},{"issue":"4","key":"95753_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis, H. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 17(4), e1003100 (2020).","journal-title":"PLoS Med."},{"issue":"6","key":"95753_CR13","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69(6), 2672\u20132682 (2019).","journal-title":"Hepatology"},{"issue":"4","key":"95753_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and united states for the period 2016\u20132030. J. Hepatol. 69(4), 896\u2013904 (2018).","journal-title":"J. Hepatol."},{"issue":"14","key":"95753_CR15","doi-asserted-by":"publisher","first-page":"1083032","DOI":"10.3389\/fendo.2023.1083032","volume":"19","author":"H Peng","year":"2023","unstructured":"Peng, H. et al. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in US adults. Front. Endocrinol. 19(14), 1083032 (2023).","journal-title":"Front. Endocrinol."},{"issue":"2","key":"95753_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cgh.2020.06.048","volume":"19","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo, S., Monti, T. & Perseghin, G. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017\u20132018 National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 19(2), 384-390.e1 (2021).","journal-title":"Clin Gastroenterol Hepatol."},{"key":"95753_CR17","first-page":"51","volume":"1","author":"YT Cao","year":"2022","unstructured":"Cao, Y. T. et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. E Clini. Med. 1, 51 (2022).","journal-title":"E Clini. Med."},{"issue":"3","key":"95753_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/children10030560","volume":"10","author":"Y Xing","year":"2023","unstructured":"Xing, Y., Fan, J., Wang, H. J. & Wang, H. Comparison of MAFLD and NAFLD Characteristics in Children. Children 10(3), 560 (2023).","journal-title":"Children"},{"issue":"7","key":"95753_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7), 1999\u20132014 (2020).","journal-title":"Gastroenterology"},{"issue":"1","key":"95753_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43066-023-00282-8","volume":"13","author":"A Attia","year":"2023","unstructured":"Attia, A., Labib, N. A., Abdelzaher, N. E., Musa, S. & Atef, M. Lifestyle determinants as a predictor of severity of metabolic associated fatty liver disease (MAFLD). Egyptian Liver J. 13(1), 47 (2023).","journal-title":"Egyptian Liver J."},{"issue":"1","key":"95753_CR21","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1038\/s41598-023-32129-y","volume":"13","author":"F Razmpour","year":"2023","unstructured":"Razmpour, F. et al. Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. Sci. Rep. 13(1), 4942 (2023).","journal-title":"Sci. Rep."},{"issue":"12","key":"95753_CR22","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.3390\/app12126165","volume":"12","author":"M G\u00f3rnicka","year":"2022","unstructured":"G\u00f3rnicka, M. et al. Anthropometric indices as predictive screening tools for obesity in adults; the need to define sex-specific cut-off points for anthropometric indices. Appl. Sci. 12(12), 6165 (2022).","journal-title":"Appl. Sci."},{"issue":"2","key":"95753_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/01.hjr.0000230096.73579.64","volume":"14","author":"F Hadaegh","year":"2007","unstructured":"Hadaegh, F., Esmaillzadeh, A. & Azizi, F. Metabolic risks in individuals with normal body mass index and normal waist circumference. Eur. J. Prev. Cardiol. 14(2), 200\u2013207 (2007).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"95753_CR24","first-page":"322","volume":"7","author":"JE Blundell","year":"2014","unstructured":"Blundell, J. E., Dulloo, A. G., Salvador, J. & Fr\u00fchbeck, G. on behalf of the EASO SAB Working Group on BMI G. Beyond BMI-phenotyping the obesities. Obesity Facts. 7(5), 322\u2013328 (2014).","journal-title":"Beyond BMI-phenotyping the obesities. Obesity Facts."},{"issue":"2","key":"95753_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/ajcn\/51.2.241","volume":"51","author":"MD Mifflin","year":"1990","unstructured":"Mifflin, M. D. et al. A new predictive equation for resting energy expenditure in healthy individuals. Am. J. Clin. Nutr. 51(2), 241\u2013247 (1990).","journal-title":"Am. J. Clin. Nutr."},{"issue":"5","key":"95753_CR26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/hep.30049","volume":"68","author":"G Kim","year":"2018","unstructured":"Kim, G. et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology 68(5), 1755\u20131768 (2018).","journal-title":"Hepatology"},{"key":"95753_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ggi.12723","volume":"16","author":"H Kim","year":"2016","unstructured":"Kim, H. et al. Sarcopenia: Prevalence and associated factors based on different suggested definitions in community-dwelling older adults. Geriatr. Gerontol. Int. 16, 110\u2013122 (2016).","journal-title":"Geriatr. Gerontol. Int."},{"issue":"11","key":"95753_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso, M. et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 36(11), 1825\u20131835 (2010).","journal-title":"Ultrasound Med. Biol."},{"issue":"1","key":"95753_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/abr.abr_114_19","volume":"8","author":"L Kamali","year":"2019","unstructured":"Kamali, L., Adibi, A., Ebrahimian, S., Jafari, F. & Sharifi, M. Diagnostic performance of ultrasonography in detecting fatty liver disease in comparison with FibroScan in people suspected of fatty liver. Adv. Biomed. Res. 8(1), 69 (2019).","journal-title":"Adv. Biomed. Res."},{"issue":"1","key":"95753_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jhep.2010.06.022","volume":"54","author":"S Gaia","year":"2011","unstructured":"Gaia, S. et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J. Hepatol. 54(1), 64\u201371 (2011).","journal-title":"J. Hepatol."},{"issue":"4","key":"95753_CR31","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","volume":"17","author":"C Hsu","year":"2019","unstructured":"Hsu, C. et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin. Gastroenterol. Hepatol. 17(4), 630\u2013637 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"95753_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15(1), 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"95753_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","volume":"69","author":"R Loomba","year":"2020","unstructured":"Loomba, R. & Adams, L. A. Advances in non-invasive assessment of hepatic fibrosis. Gut 69(7), 1343\u20131352 (2020).","journal-title":"Gut"},{"issue":"92","key":"95753_CR34","first-page":"5756","volume":"1","author":"MF Shalaby","year":"2023","unstructured":"Shalaby, M. F. et al. Prevalence and Possible Risk Factors of Metabolic Associated Fatty Liver Disease (MAFLD) in Non-Obese Individuals in El-Minia Governorate-Egypt. Egyp. J. Hospital Med. 1(92), 5756\u20135762 (2023).","journal-title":"Egyp. J. Hospital Med."},{"issue":"8","key":"95753_CR35","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/v15081730","volume":"15","author":"L Rinaldi","year":"2023","unstructured":"Rinaldi, L. et al. Non-invasive measurement of hepatic fibrosis by transient elastography: a narrative review. Viruses 15(8), 1730 (2023).","journal-title":"Viruses"},{"key":"95753_CR36","first-page":"1","volume":"27","author":"M Eslam","year":"2025","unstructured":"Eslam, M. et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hep. Intl. 27, 1\u201341 (2025).","journal-title":"Hep. Intl."},{"issue":"9","key":"95753_CR37","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1016\/j.sjbs.2021.05.063","volume":"28","author":"AS Alamri","year":"2021","unstructured":"Alamri, A. S. et al. Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. Saudi J. Biol. Sci. 28(9), 4921\u20134925 (2021).","journal-title":"Saudi J. Biol. Sci."},{"key":"95753_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12199-008-0074-5","volume":"14","author":"K Tominaga","year":"2009","unstructured":"Tominaga, K. et al. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ. Health Prev. Med. 14, 142\u2013149 (2009).","journal-title":"Environ. Health Prev. Med."},{"key":"95753_CR39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00535-009-0198-4","volume":"45","author":"G Tsuruta","year":"2010","unstructured":"Tsuruta, G. et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. J. Gastroenterol. 45, 666\u2013672 (2010).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"95753_CR40","first-page":"83","volume":"6","author":"A Dahshan","year":"2009","unstructured":"Dahshan, A., Chalmers, L. J. & Tolia, V. Nonalcoholic fatty liver disease in children. Clini. Practice. 6(1), 83 (2009).","journal-title":"Clini. Practice."},{"issue":"6","key":"95753_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1159\/000235677","volume":"55","author":"J Frith","year":"2009","unstructured":"Frith, J., Day, C. P., Henderson, E., Burt, A. D. & Newton, J. L. Non-alcoholic fatty liver disease in older people. Gerontology 55(6), 607\u2013613 (2009).","journal-title":"Gerontology"},{"issue":"1","key":"95753_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000780","volume":"8","author":"S Tomah","year":"2021","unstructured":"Tomah, S. et al. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastroenterol. 8(1), e000780 (2021).","journal-title":"BMJ Open Gastroenterol."},{"issue":"11","key":"95753_CR43","doi-asserted-by":"publisher","first-page":"1290842","DOI":"10.3389\/fpubh.2023.1290842","volume":"30","author":"MA Hegazy","year":"2024","unstructured":"Hegazy, M. A., Elshafei, A., Salem, M. R., Ashoush, O. & Abdelghani, A. Non-alcoholic fatty liver disease related knowledge among a sample of Egyptians: an exploratory cross-sectional study. Front. Public Health 30(11), 1290842 (2024).","journal-title":"Front. Public Health"},{"issue":"12","key":"95753_CR44","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(21)00275-2","volume":"6","author":"CW Spearman","year":"2021","unstructured":"Spearman, C. W. et al. Non-alcoholic Fatty Liver Disease in Sub-Saharan Africa 1 Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol. Hepatol. 6(12), 1036\u20131046 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"95753_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7196\/SAMJ.1422","volume":"100","author":"FC Kruger","year":"2010","unstructured":"Kruger, F. C. et al. Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: A descriptive analysis. SAMJ South Afr. Med. J. 100(3), 168\u2013171 (2010).","journal-title":"SAMJ South Afr. Med. J."},{"issue":"11","key":"95753_CR46","doi-asserted-by":"publisher","first-page":"1291501","DOI":"10.3389\/fmed.2024.1291501","volume":"23","author":"M Habibullah","year":"2024","unstructured":"Habibullah, M. et al. Metabolic-associated fatty liver disease: A selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Front. Med. 23(11), 1291501 (2024).","journal-title":"Front. Med."},{"issue":"7","key":"95753_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4254\/wjh.v13.i7.790","volume":"13","author":"A Atsawarungruangkit","year":"2021","unstructured":"Atsawarungruangkit, A. et al. Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United States\u2019 adolescent population. World J. Hepatol. 13(7), 790 (2021).","journal-title":"World J. Hepatol."},{"issue":"3","key":"95753_CR48","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","volume":"20","author":"RJ Wong","year":"2022","unstructured":"Wong, R. J. & Cheung, R. Trends in the prevalence of metabolic dysfunction\u2013associated fatty liver disease in the United States, 2011\u20132018. Clin. Gastroenterol. Hepatol. 20(3), e610\u2013e613 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"95753_CR49","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/liv.14828","volume":"41","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo, S. & Perseghin, G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 41(6), 1290\u20131293 (2021).","journal-title":"Liver Int."},{"issue":"6","key":"95753_CR50","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim, D. et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J. Hepatol. 75(6), 1284\u20131291 (2021).","journal-title":"J. Hepatol."},{"issue":"4","key":"95753_CR51","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","volume":"20","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin. Gastroenterol. Hepatol. 20(4), e855\u2013e875 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"95753_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.hnm.2023.200210","volume":"27","author":"S Bansal","year":"2023","unstructured":"Bansal, S., Vachher, M., Arora, T., Kumar, B. & Burman, A. Visceral fat: A key mediator of NAFLD development and progression. Hum. Nutrition Metabolism. 27, 200210 (2023).","journal-title":"Hum. Nutrition Metabolism."},{"issue":"1","key":"95753_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41387-024-00339-6","volume":"14","author":"J Yang","year":"2024","unstructured":"Yang, J. et al. Associations of traditional healthy lifestyle and sleep quality with metabolic dysfunction-associated fatty liver disease: two population-based studies. Nutr. Diabetes 14(1), 79 (2024).","journal-title":"Nutr. Diabetes"},{"issue":"7","key":"95753_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102412","volume":"48","author":"S Demirci","year":"2024","unstructured":"Demirci, S. et al. Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: An observational study with ISarcoPRM algorithm. Clin. Res. Hepatol. Gastroenterol. 48(7), 102412 (2024).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"12","key":"95753_CR55","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.3390\/cells10123401","volume":"10","author":"D Ramai","year":"2021","unstructured":"Ramai, D. et al. Progressive liver fibrosis in non-alcoholic fatty liver disease. Cells 10(12), 3401 (2021).","journal-title":"Cells"},{"issue":"2","key":"95753_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/cpf.12152","volume":"35","author":"M\u00d8 Fosb\u00f8l","year":"2015","unstructured":"Fosb\u00f8l, M. \u00d8. & Zerahn, B. Contemporary methods of body composition measurement. Clin. Physiol. Funct. Imaging 35(2), 81\u201397 (2015).","journal-title":"Clin. Physiol. Funct. Imaging"},{"key":"95753_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-015-0510-9","volume":"16","author":"F Buckinx","year":"2015","unstructured":"Buckinx, F. et al. Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. BMC Musculoskelet. Disord. 16, 1\u20137 (2015).","journal-title":"BMC Musculoskelet. Disord."},{"issue":"7","key":"95753_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200465","volume":"13","author":"N Achamrah","year":"2018","unstructured":"Achamrah, N. et al. Comparison of body composition assessment by DXA and BIA according to the body mass index: A retrospective study on 3655 measures. PLoS ONE 13(7), e0200465 (2018).","journal-title":"PLoS ONE"},{"issue":"2","key":"95753_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41430-018-0335-3","volume":"73","author":"LC Ward","year":"2019","unstructured":"Ward, L. C. Bioelectrical impedance analysis for body composition assessment: reflections on accuracy, clinical utility, and standardisation. Eur. J. Clin. Nutr. 73(2), 194\u2013199 (2019).","journal-title":"Eur. J. Clin. Nutr."},{"issue":"4","key":"95753_CR60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/sjg.SJG_29_20","volume":"26","author":"FA Alsaif","year":"2020","unstructured":"Alsaif, F. A. et al. Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi J. Gastroenterol. 26(4), 204\u2013209 (2020).","journal-title":"Saudi J. Gastroenterol."},{"issue":"1","key":"95753_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.rpped.2015.05.007","volume":"34","author":"AP Clemente","year":"2016","unstructured":"Clemente, A. P. et al. Circunfer\u00eancia da cintura como marcador para triagem de doen\u00e7a hep\u00e1tica gordurosa n\u00e3o alco\u00f3lica em adolescentes obesos (Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents). Rev Paul Pediatr. 34(1), 47\u201355 (2016).","journal-title":"Rev Paul Pediatr."},{"issue":"2","key":"95753_CR62","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/jcsm.12901","volume":"13","author":"CW Li","year":"2022","unstructured":"Li, C. W. et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J. Cachexia. Sarcopenia Muscle 13(2), 781\u2013794 (2022).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"4","key":"95753_CR63","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/nu15040891","volume":"15","author":"M Iwaki","year":"2023","unstructured":"Iwaki, M. et al. Impact of sarcopenia on non-alcoholic fatty liver disease. Nutrients 15(4), 891 (2023).","journal-title":"Nutrients"},{"issue":"2","key":"95753_CR64","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","volume":"78","author":"B Fromenty","year":"2023","unstructured":"Fromenty, B. & Roden, M. Mitochondrial alterations in fatty liver diseases. J. Hepatol. 78(2), 415\u2013429 (2023).","journal-title":"J. Hepatol."},{"issue":"1","key":"95753_CR65","doi-asserted-by":"publisher","first-page":"e0191388","DOI":"10.1371\/journal.pone.0191388","volume":"13","author":"NH Naran","year":"2018","unstructured":"Naran, N. H., Haagensen, M. & Crowther, N. J. Steatosis in South African women: How much and why?. PLoS ONE 13(1), e0191388 (2018).","journal-title":"PLoS ONE"},{"issue":"8","key":"95753_CR66","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai, Y., Kubota, N., Yamauchi, T. & Kadowaki, T. Role of insulin resistance in MAFLD. Int. J. Mol. Sci. 22(8), 4156 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"95753_CR67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000538426","volume":"42","author":"P Lemmer","year":"2024","unstructured":"Lemmer, P. et al. Liver Stiffness Determined by Transient Elastography Is a Simple and Highly Accurate Predictor for Presence of Liver Cirrhosis in Clinical Routine. Dig. Dis. 42(3), 265\u2013275 (2024).","journal-title":"Dig. Dis."},{"issue":"10","key":"95753_CR68","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","volume":"18","author":"O Juanola","year":"2021","unstructured":"Juanola, O., Mart\u00ednez-L\u00f3pez, S., Franc\u00e9s, R. & G\u00f3mez-Hurtado, I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Public Health 18(10), 5227 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"95753_CR69","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12916-022-02672-y","volume":"20","author":"H Kolb","year":"2022","unstructured":"Kolb, H. Obese visceral fat tissue inflammation: from protective to detrimental?. BMC Med. 20(1), 494 (2022).","journal-title":"BMC Med."},{"issue":"4","key":"95753_CR70","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3350\/cmh.2023.0250","volume":"29","author":"E Han","year":"2023","unstructured":"Han, E. & Lee, Y. H. Lean or non-obese nonalcoholic fatty liver disease patients: Are they really lean?. Clin. Mol. Hepatol. 29(4), 980 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"9","key":"95753_CR71","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.numecd.2023.06.004","volume":"33","author":"K B\u00f3dis","year":"2023","unstructured":"B\u00f3dis, K. et al. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 33(9), 1785\u20131796 (2023).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"1","key":"95753_CR72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s43066-024-00326-7","volume":"14","author":"G Esmat","year":"2024","unstructured":"Esmat, G. et al. Obesity prevalence in adults and patients with hepatitis C: results from screening a population of 50 million in Egypt. Egyp. Liver J. 14(1), 22 (2024).","journal-title":"Egyp. Liver J."},{"issue":"1","key":"95753_CR73","first-page":"46","volume":"1","author":"YI El Nahass","year":"2020","unstructured":"El Nahass, Y. I., Darwish, M. K. & Mogawer, S. PNPLA3 and GCKR Gene Polymorphisms influence genetic Susceptibility to NAFLD in Obese Egyptians. Front. Sci. Res. Technol. 1(1), 46\u201351 (2020).","journal-title":"Front. Sci. Res. Technol."},{"issue":"4","key":"95753_CR74","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3390\/ijerph19042096","volume":"19","author":"Q Yuan","year":"2022","unstructured":"Yuan, Q. et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int. J. Environ. Res. Public Health 19(4), 2096 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"95753_CR75","first-page":"1","volume":"22","author":"Y Li","year":"2024","unstructured":"Li, Y. & Tan, S. Sleep factors were associated with a higher risk of MAFLD and significant fibrosis. Sleep and Breathing. 22, 1\u20131 (2024).","journal-title":"Sleep and Breathing."},{"key":"95753_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-01782-w","volume":"21","author":"YL Chen","year":"2021","unstructured":"Chen, Y. L. et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 21, 1\u20132 (2021).","journal-title":"BMC Gastroenterol."},{"issue":"7","key":"95753_CR77","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/biom14070845","volume":"14","author":"M Lodge","year":"2024","unstructured":"Lodge, M., Dykes, R. & Kennedy, A. Regulation of fructose metabolism in Nonalcoholic Fatty Liver Disease. Biomolecules 14(7), 845 (2024).","journal-title":"Biomolecules"},{"key":"95753_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2025.2471871","author":"A Giannakodimos","year":"2025","unstructured":"Giannakodimos, A. et al. Arterial stiffness as a complication of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Expert Rev. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1080\/17474124.2025.2471871 (2025).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"95753_CR79","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s12072-024-10673-7","volume":"18","author":"Z Pan","year":"2024","unstructured":"Pan, Z. et al. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hep. Intl. 18(3), 964\u2013972 (2024).","journal-title":"Hep. Intl."},{"issue":"3","key":"95753_CR80","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1111\/liv.70042","volume":"45","author":"LA Patmore","year":"2025","unstructured":"Patmore, L. A. et al. The Association between metabolic dysfunction-associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B. Liver Int. 45(3), e70042 (2025).","journal-title":"Liver Int."},{"key":"95753_CR81","unstructured":"Hoang T, Lee J, Kim BH, Cho Y, Kim J. Evaluation of Nomenclature of Fatty Liver Disease in Association with Hepatocellular Carcinoma: A 14.5-Year Cohort Study in Korea. Cancer research and treatment."},{"issue":"5","key":"95753_CR82","doi-asserted-by":"publisher","first-page":"101512","DOI":"10.1016\/j.aohep.2024.101512","volume":"29","author":"Z Pan","year":"2024","unstructured":"Pan, Z. et al. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Ann. Hepatol. 29(5), 101512 (2024).","journal-title":"Ann. Hepatol."},{"issue":"7","key":"95753_CR83","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/liv.15931","volume":"44","author":"Z Pan","year":"2024","unstructured":"Pan, Z., Shiha, G., Esmat, G., M\u00e9ndez-S\u00e1nchez, N. & Eslam, M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 44(7), 1567\u20131574 (2024).","journal-title":"Liver Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95753-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95753-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95753-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:02:49Z","timestamp":1744988569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95753-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95753"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95753-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted after obtaining approval from the local ethics committee, Faculty of Medicine, Suez University (Approval No. 32). All subjects were informed and gave their voluntary, written informed consent. It is declared that all methods were carried out following relevant guidelines and regulations. It was performed according to the recommendations of Good Clinical Practice and the Declaration of Helsinki (2013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"13470"}}